Aethlon Medical, Inc. (AEMD), a therapeutic company developing treatments for cancer and infectious diseases, has priced a public offering of 5 million common shares and accompanying warrants at $0.90 each.
The warrants, exercisable immediately at $0.90, will expire five years from issuance. The closing is expected around September 5, 2025, subject to customary conditions.
The offering is projected to raise gross proceeds of approximately $4.5 million, which the company plans to use for corporate purposes, including clinical trials, R&D, capital expenditures, and working capital.
AEMD currently trades at $0.7295 or 45.9630% lower on the NasdaqCM.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.